MedTrace Logo

EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors

NCT02623764 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 218

Last updated 2018-08-17

No results posted yet for this study

Summary

Drug treatment with cholinesterase inhibitors is indicated for treatment of Alzheimer´s disease and in most cases, one of these drugs is prescribed as soon as the diagnosis has been made. Nevertheless, it has been shown in several studies that up to 30% of patients do not benefit from treatment. These drugs can have side effects, most frequently from the gastrointestinal tract with nausea, diarrhea and discomfort in the abdomen as the most frequent signs. It is therefore important to know before the treatment is initiated if the patient will likely benefit from the drug or not. It is not possible today with current knowledge but this project aims to evaluate a specific index, calculated from an EEG registration (the EEG-cholinergic index) for this purpose. A conventional EEG registration is done before treatment and the cholinergic index calculated from the EEG registration is compared to the clinical outcome. The duration of follow up is 6 months with an extension of further 6 months.

Conditions

  • Alzheimer´s Disease

Sponsors & Collaborators

  • Mentis Cura

    collaborator INDUSTRY

  • Landspitali University Hospital

    lead OTHER

Principal Investigators

  • Jon Snaedal, MD · Professor

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2019-05-31
Completion
2019-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02623764 on ClinicalTrials.gov